MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-DL-06-0051196
Rapross Pharmaceuticals Private Limited - pharma in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2023
₹29.39 Cr
▲ 3% YoY
Net profit · FY 2023
₹1.38 Cr
Net margin 4.7%
EBITDA · FY 2023
₹2.65 Cr
EBITDA margin 9%
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹25 Lakh
Issued & subscribed
Satisfied charges
₹5 Cr
No open charges
Company age
31 yrs
Est. 1995
Employees · EPFO
326
Provident fund records
About Rapross Pharmaceuticals Private Limited
Data last updated:
Rapross Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 22 March 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74899DL1995PTC066606. Its GSTIN is 07AAACR4327A1ZX (Delhi). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹25 Lakh. It is led by directors including Parveen Kumar Bansal and Ranjan Verma.
Its last annual general meeting (AGM) was held on 28 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at II Floor Garg Plaza 5 Community Centre Sector – 8 Rohini, Delhi, India – 110085.
As per the financials filed for FY 2023, the company reported a revenue of ₹29.39 Cr, a growth of 3% compared to the previous year. For the same year it recorded a net profit of ₹1.38 Cr (net margin 4.7%) and EBITDA of ₹2.65 Cr (EBITDA margin 9%). Revenue has declined at a compounded annual rate (CAGR) of 1% over three years and 3% over five years.
The company has about 326 employees on its provident fund (EPFO) records.
As per MCA filings, the company has satisfied charges of ₹5 Cr on record. Court records list 11 cases involving the company, including 7 filed by the company and 4 filed against it; 4 cases are pending.
Rapross Pharmaceuticals Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-06-0051196). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website raprosspharma.com.
Company details
CIN U74899DL1995PTC066606
Registration Number 066606
Incorporation Date 22 March 1995
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 28 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-DL-06-0051196
Key People
Nimit Bansal Additional Director Sharad Verma Additional Director Parveen Kumar Bansal Director Recognitions & Rankings of Rapross Pharmaceuticals
Contact details
Rapross Pharmaceuticals Private Limited's registered office is in Delhi, Delhi. Its website is raprosspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressII Floor Garg Plaza 5 Community Centre Sector – 8 Rohini, Delhi, India – 110085
- IndustryPharma, API Manufacturers
To see the full contact details of Rapross Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Rapross Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Rapross Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Rapross Pharmaceuticals Private Limited, buy the company report.
Financials of Rapross Pharmaceuticals Private Limited
FY 2024 filings availableRapross Pharmaceuticals Private Limited reported revenue of ₹29.39 Cr (up 3% YoY) for FY 2023.
Revenue · FY 2023
₹29.39 Cr ▲ 3%
Net profit · FY 2023
₹1.38 Cr margin 4.7%
EBITDA · FY 2023
₹2.65 Cr margin 9%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 3%
3 years · compounded
▼ 1%
5 years · compounded
▼ 3%
EBITDA CAGR growth
1 year
▲ 10%
3 years · compounded
▲ 8%
5 years · compounded
▲ 4%
Revenue rose 3% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 3%. EBITDA rose 10% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹29.39 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹2.65 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.38 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9% | ||||
| Net Profit Margin | 4.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rapross Pharmaceuticals Private Limited, buy the company report.
Board of directors of Rapross Pharmaceuticals Private Limited
Rapross Pharmaceuticals has 5 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nimit Bansal | Additional Director | 01 Sep 2023 | 3 Years 1 Months | Current |
| Sharad Verma | Additional Director | 01 Sep 2023 | 3 Years 1 Months | Current |
| Parveen Kumar Bansal | Director | 04 Apr 1995 | 31 Years 6 Months | Current |
| Ranjan Verma | Director | 04 Apr 1995 | 31 Years 6 Months | Current |
| Shailendra Singh | Additional Director | 11 Aug 2025 | 1 Years 2 Months | Current |
Peer comparison
Rapross Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pellsys Pharma Private Limited | ₹29.54 Cr (FY 2025) | -3.0% | Hyderabad, Telangana, India | |||
| Medion Biotech Private Limited | ₹29.5 Cr (FY 2025) | 1.0% | Delhi, India | |||
| Rapross Pharmaceuticals Private Limitedthis company | ₹29.39 Cr (FY 2023) | ₹1.38 Cr | 4.7% | 3.0% | 326 | Delhi, India |
| Puerto Life Sciences Private Limited | ₹29.22 Cr (FY 2025) | -10.0% | Delhi, India | |||
| Saf Fermion Ltd. | ₹29.2 Cr (FY 2025) | 3.0% | Kolkata, West Bengal, India | |||
| Universal Pharmaceuticals Private Limited | ₹29.2 Cr (FY 2025) | 189.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Rapross Pharmaceuticals Private Limited, buy the company report.
Auditor
Rapross Pharmaceuticals Private Limited is audited by ANM & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| ANM & Associates | FY 2023 | 008263N |
Shareholding
The shareholding of Rapross Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Rapross Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 Jul 2022 | 100597623 | Axis Bank Limited | ₹5 Cr | Satisfied |
To see the full charge records of Rapross Pharmaceuticals Private Limited, buy the company report.
Total charge records: 1 View all charges
Legal cases
Rapross Pharmaceuticals Private Limited has 11 court cases on record: 7 filed by Rapross Pharmaceuticals, 4 filed against it. 4 cases are pending and 7 are disposed.
Total cases
11
Filed by the company
7
Filed against the company
4
Pending
4
Disposed
7
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 10 | 4 | 3 |
| High courts | 1 | 0 | 1 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North West, Delhi | Cheque dishonour complaint | Filed by the company against Torkem Pharmaceuticals Private Limited | Pending |
| District court, Central, Delhi | Interim or miscellaneous application | Filed by the company against Solace Biotech Ltd. | Disposed |
| District court, Ambala, Haryana | Execution petition | Filed by the company against an individual | Pending |
| High Court of Delhi | Writ petition | Filed by the company against Union of India & Anr. | Pending |
| District court, North, Delhi | Civil suit | Filed by the company against Baroque Pharmaceuticals | Pending |
To see the full case history of Rapross Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Rapross Pharmaceuticals Private Limited has 3 MSME Form 1 returns on record between 2020 and 2024, listing 15 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 7)
To see the full MSME payment records of Rapross Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Rapross Pharmaceuticals Private Limited has a workforce of 326 employees on its EPFO records as of Mar 20, 2025, across 1 active EPFO establishment.
Employee count
326
Active EPFO establishments
1
Employee growth
10.51%
GST
Rapross Pharmaceuticals has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACR4327A1ZX | Delhi | Active | 01 Jul 2017 |
| 06AAACR4327A1ZZ | Haryana | Active | 19 Feb 2022 |
To see the full GST registrations and return filing status of Rapross Pharmaceuticals Private Limited, buy the company report.
Recent activity
Rapross Pharmaceuticals Private Limited has 9 board changes on record since 1995: 6 appointments and 3 cessations. The latest: Shailendra Singh was appointed as Additional Director on 11 Aug 2025.
Appointed
Shailendra Singh was appointed as Additional Director.
AGM
Rapross Pharmaceuticals Private Limited last Annual general meeting of members was held on 28 Sep 2024 as per latest MCA records.
Filing
Rapross Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Appointed
Karam Vir Verma was appointed as Additional Director.
Ceased
Navneet Bagga ceased to be Additional Director.
Appointed
Nimit Bansal was appointed as Additional Director.
Appointed
Sharad Verma was appointed as Additional Director.
Charges
A charge registered on 04 Jul 2022 via Charge ID 100597623 with Axis Bank Limited was fully satisfied on 28 Aug 2023.
Charges
A charge with Axis Bank Limited amounted to Rs. 5.00 Cr with Charge ID 100597623 was registered on 04 Jul 2022.
Ceased
Parveen Kumar Bansal ceased to be Director.
Ceased
Kanika Jain ceased to be Director.
Appointed
Parveen Kumar Bansal was appointed as Director.
2 earlier events are in the company report.
Frequently asked questions
Rapross Pharmaceuticals is an active private limited company based in Delhi, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 22 March 1995 (31+ years old) and is registered under CIN U74899DL1995PTC066606.
Rapross Pharmaceuticals has 5 current directors:
- Nimit Bansal - Additional Director
- Sharad Verma - Additional Director
- Parveen Kumar Bansal - Director
- Ranjan Verma - Director
- Shailendra Singh - Additional Director
The latest financial statements of Rapross Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 28 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Rapross Pharmaceuticals is 07AAACR4327A1ZX, registered in Delhi. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 06AAACR4327A1ZZ (Haryana).
The CIN (Corporate Identification Number) of Rapross Pharmaceuticals is U74899DL1995PTC066606. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rapross Pharmaceuticals has 11 court cases on record: 7 filed by the company and 4 filed against it. 4 are pending. Most are in the district courts.
Rapross Pharmaceuticals was incorporated on 22 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Rapross Pharmaceuticals by revenue are Pellsys Pharma Private Limited, Medion Biotech Private Limited, Puerto Life Sciences Private Limited, Saf Fermion Ltd, Universal Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Shailendra Singh was appointed as Additional Director on 11 Aug 2025. Karam Vir Verma was appointed as Additional Director on 01 Feb 2024. Navneet Bagga ceased to be Additional Director on 01 Feb 2024. Rapross Pharmaceuticals has 9 board changes on record in total.
Yes, Rapross Pharmaceuticals is registered as a small enterprise under Udyam registration (number: UDYAM-DL-06-0051196).
Rapross Pharmaceuticals has 3 MSME Form 1 returns on record between 2020 and 2024, listing 15 overdue payments to 7 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Rapross Pharmaceuticals can be reached through the website raprosspharma.com. Its registered office is in Delhi, India.